ZYME
ZymeworksDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Positive clinical readouts and a strategic partner deal de-risk the pipeline, accelerate cash inflows, and justify meaningful re-rating toward the high-30s per share on deal multiples and peer comps.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.6.
What can break
Clinical setbacks or the need for dilutive financing compress valuation; absent catalytic BD, downside to the high-teens is plausible given binary trial risk and limited near-term revenues.
Momentum
37
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.49 · Bull $34.99 · Bear $17.49
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $39.33
Why
Momentum37 · Δ7d -29.7
Value41 · Δ7d +0.1
Sentiment59 · Δ7d +1.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
37
26% active weight
Current posture
7d trendSoftening
Δ7d
-29.7
Δ21d
+18.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
59
34% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
-2.7
Why this grade
Composite grade D. Momentum 36.6 / Value 41.1 / Sentiment 59.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.77B
Beta
1.25
Shares Out
73.57M
P/E (TTM) · Derived
-22.4
P/S (TTM)
14.18
P/FCF (TTM) · Derived
-23.34
Rev YoY
-91.1%
EPS YoY
+95.2%
Gross Margin
+87.3%
Op Margin
-52.5%
Net Debt
-$210.53M
Current Ratio
10.82
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology